Stay updated on Pediatric Immunotherapy Clinical Trial
Sign up to get notified when there's something new on the Pediatric Immunotherapy Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F9foTlMYemt0XIEcX4vfL88ivaSU.uncropped.jpg&w=3840&q=75)
Latest updates to the Pediatric Immunotherapy Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoChange DetectedThe study has expanded to include 14 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Interventional Model Description: Phase I: To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to adolescents 12-21 years with progressive, relapsed, refractory high-risk solid tumors and CNS tumors To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to children 6-11 years with progressive, relapsed, refractory high-risk solid tumors and CNS Tumors Phase II: To evaluate activity and safety of the combination treatment with nivolumab and entinostat in children and adolescents aged 2-21 years with refractory/relapsed/progressive high-risk solid tumors and CNS tumors with: Group A: a high mutational load (> 100 somatic SNVs/exome), Group C: Focal MYC(N) amplification or ATRT-MYC subgroup, Group E: high TILs or TLS positive (> 600 cells/mm² or presence of TLS). Show less Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Nivolumab and Entinostat Combination Study of Nivolumab and Entinostat Drug : Nivolumab and Entinostat Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.SummaryDifference42%
Stay in the know with updates to Pediatric Immunotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pediatric Immunotherapy Clinical Trial page.